Skip to main content
placeholder image

Is there an early role for LAls (long-acting injectable antipsychotics)?

Conference Paper


Abstract


  • Evidence for pharmacological intervention favourably affects symptomatic control and functional outcomes during early phase of illness in schizophrenia, as well established. Thus the primary goal of treatment during this period is to prevent

    a subsequent relapse and to restore socio-occupational functioning to the premorbid level. However, current li .teralu highlight that the poor medication adherence is particularly common in FES and is among the leading reasons for relap tee in FES. Several guidelines recommend LAI AP medication only for patients with recurrent relapses related to partial or full nonadherence, or patients with persistent positive symptoms. However, most recent guidelines recommend that tile clinicians consider LAI antipsychotics in patients who are inadequately adherent 'at any stage'. For the treatment of Hrsl and early episode Schizophrenia, current guidelines have a conservative position, but recent evidence emphasizes the need to be updated, given the importance of continuous treatment in the early phases of schizophrenia. LAI antip ycholics may also be a treatment option in the context of a shared decision-making approach as it could reduce the negative image and stigmatization attached to depots. Tolerability of antipsychotics is a particular concern in FES as medication-naive individuals are acutely sensitive to APs in terms of responsiveness as well as side effects including extrapyramidal ymptorns (EPS) and weight gain. However, it is generally admitted that LAis have a more acceptable side effect profile in comparison with their oral counterparts due to lower variation in peak and trough levels. This presentation debates the role of LAis ·j n an early phase of Schizophrenia.

Publication Date


  • 2018

Citation


  • Pai, N. B. (2018). Is there an early role for LAls (long-acting injectable antipsychotics)?. WFSBP 2018 (pp. 98-98).

Start Page


  • 98

End Page


  • 98

Abstract


  • Evidence for pharmacological intervention favourably affects symptomatic control and functional outcomes during early phase of illness in schizophrenia, as well established. Thus the primary goal of treatment during this period is to prevent

    a subsequent relapse and to restore socio-occupational functioning to the premorbid level. However, current li .teralu highlight that the poor medication adherence is particularly common in FES and is among the leading reasons for relap tee in FES. Several guidelines recommend LAI AP medication only for patients with recurrent relapses related to partial or full nonadherence, or patients with persistent positive symptoms. However, most recent guidelines recommend that tile clinicians consider LAI antipsychotics in patients who are inadequately adherent 'at any stage'. For the treatment of Hrsl and early episode Schizophrenia, current guidelines have a conservative position, but recent evidence emphasizes the need to be updated, given the importance of continuous treatment in the early phases of schizophrenia. LAI antip ycholics may also be a treatment option in the context of a shared decision-making approach as it could reduce the negative image and stigmatization attached to depots. Tolerability of antipsychotics is a particular concern in FES as medication-naive individuals are acutely sensitive to APs in terms of responsiveness as well as side effects including extrapyramidal ymptorns (EPS) and weight gain. However, it is generally admitted that LAis have a more acceptable side effect profile in comparison with their oral counterparts due to lower variation in peak and trough levels. This presentation debates the role of LAis ·j n an early phase of Schizophrenia.

Publication Date


  • 2018

Citation


  • Pai, N. B. (2018). Is there an early role for LAls (long-acting injectable antipsychotics)?. WFSBP 2018 (pp. 98-98).

Start Page


  • 98

End Page


  • 98